罗格列酮与全反式维甲酸对人胃癌SGC7901细胞株生长和凋亡的影响

Objective To investigate the influence of PPARγ excitomotor RSG and ATRA on gastric cancer SGC7901 cell line proliferation in vitro and its potential mechanism study.Methods Human gastric cancer SGC7901 cell line was cultured in vitro.Experiment samples were divided to blank group,10μmol/L ATRA group, 12.5μmol/L RSG group, 25μmol/L RSG group, 10μmol/L ATRA + 25μmol/L RSG group.Proliferation inhibitory effect was determined by MTI assay.Flow cytometry was used to detect cell cycle, H.E stain was used to observed micrography alteration.Expression of PPARγ protein in gastric cancer cells were measured by immunohistochemistry.PPARγ mRNA in gastric cancer cells were measured by RT-PCR.Results ATAR at concentration 10μmol/L, RSG at 12.5 μmol/L and RSG at 25 μmol/L could inhibit the proliferation of SGC7901 cells in a dose-and time-dependent, and when both agents were combined for 72h, growth inhibition ratio was (29.73 ± 0.69) %.Flow cytometry analysis revealed a cell cycle arrest at G1 and S phase, and when both agents combined, S% was (12.87 ± 0.35 )%, cell micrography tended to be normal when both agents combined.Up-regulation of PPARγ protein and PPARγ mRNA expressions were also observed, those effects were enhanced when both agents combined, and grey scale ratio was 0.646.Conclusion The ATRA and RSG could significantly induced growth inhibition of human gastric cancer SGC7901 cell, which may be associated with cell cycle arrest and inducing differentiation, activation of PPARγ protein and PPARγ mRNA expression.Synergistic effect could be caused by the combined use of the two agents.     

胃癌组织Tiam1和CD44V6及Ecadherin表达与分化程度相关性的研究

目的:探讨Tiam1、CD44V6和Ecadherin在胃癌组织中的表达及其与病理生物学行为的关系.方法:应用RT-PCR和SP法对56例胃癌和15例正常胃黏膜组织进行Tiam1、CD44V6和Ecadherin蛋白检测.结果:与正常胃黏膜组织相比,Tiam1和CD44V6在胃癌组织中高表达(χ2=32.92,P=0.000;χ2=5.63,P=0.018),Ecadherin在胃癌组织中低表达(χ2=10.99,P=0.001);胃癌组织Tiam1、CD44V6和Ecadherin的表达与组织分化程度密切相关(χ2=5.48,P=0.022;χ2=5.72,P=0.016;χ2=5.63,P=0.018);Spearman等级相关分析显示,Tiam1与CD44V6的表达呈正相关(rs=0.576,P=0.000),Tiam1与Ecadherin的表达呈负相关(rs=-0.428,P=0.001).结论:Tiam1、CD44V6和Ecadherin的表达与胃癌的发生、发展和分化程度密切相关.     

罗格列酮与全反式维甲酸对人胃癌SGC7901细胞株生长和凋亡的影响

Objective To investigate the influence of PPARγ excitomotor RSG and ATRA on gastric cancer SGC7901 cell line proliferation in vitro and its potential mechanism study.Methods Human gastric cancer SGC7901 cell line was cultured in vitro.Experiment samples were divided to blank group,10μmol/L ATRA group, 12.5μmol/L RSG group, 25μmol/L RSG group, 10μmol/L ATRA + 25μmol/L RSG group.Proliferation inhibitory effect was determined by MTI assay.Flow cytometry was used to detect cell cycle, H.E stain was used to observed micrography alteration.Expression of PPARγ protein in gastric cancer cells were measured by immunohistochemistry.PPARγ mRNA in gastric cancer cells were measured by RT-PCR.Results ATAR at concentration 10μmol/L, RSG at 12.5 μmol/L and RSG at 25 μmol/L could inhibit the proliferation of SGC7901 cells in a dose-and time-dependent, and when both agents were combined for 72h, growth inhibition ratio was (29.73 ± 0.69) %.Flow cytometry analysis revealed a cell cycle arrest at G1 and S phase, and when both agents combined, S% was (12.87 ± 0.35 )%, cell micrography tended to be normal when both agents combined.Up-regulation of PPARγ protein and PPARγ mRNA expressions were also observed, those effects were enhanced when both agents combined, and grey scale ratio was 0.646.Conclusion The ATRA and RSG could significantly induced growth inhibition of human gastric cancer SGC7901 cell, which may be associated with cell cycle arrest and inducing differentiation, activation of PPARγ protein and PPARγ mRNA expression.Synergistic effect could be caused by the combined use of the two agents.     

呼吸机辅助治疗有机磷中毒呼吸衰竭患者的护理

目的探讨呼吸机在重度有机磷中毒呼吸衰竭患者治疗中的应用及护理。方法本组52例有机磷中毒呼吸衰竭患者均采用呼吸机辅助治疗，根据患者呼吸状况和动脉血气分析参数设定呼吸机工作模式及参数，同时加强呼吸机管道及患者口腔、气道的各种护理措施。结果治愈41N（78．8％），家属放弃治疗2例（3．9％），死亡9例（17．3％）。发生呼吸机相关性肺炎31例（59．6％），治愈25例（80．6％），死亡6例（19．4％）。结论根据患者呼吸状况和动脉血气分析参数设定呼吸机工作模式及参数，加强呼吸机管道和患者气道护理，对于提高重度有机磷中毒呼吸衰竭患者的存活率具有重要意义。     

TA方案治疗初治成人急性髓性白血病的临床观察

目的 探讨TA方案治疗初治成人急性髓性白血病的疗效及毒副反应.方法 将初治急性髓性白血病(M3除外)患者65例随机分为TA(吡柔比星联合阿糖胞苷)治疗组和DA(柔红霉素联合阿糖胞苷)对照组, 化疗2个周期后观察两组的临床疗效及毒副反应.结果 治疗组完全缓解率(CR) 67.6%,部分缓解率(PR)18.9%;对照组CR57.1%,PR 7.1%.骨髓抑制情况:治疗组粒缺持续时间为(8.23±1.52 )d,外周白细胞(WBC)最低值(0.35±0.12)×109/L,输血小板(PLT)量(机采单位) (2.19±0.59).对照组粒缺持续时间为(5.51±1.31)d,WBC最低值(0.43±0.11)×109/L,输PLT量(机采单位)(1.86±0.73).感染发生率治疗组为100%,对照组为85.7%.胃肠道反应:治疗组24(64.9%)例,对照组25(89.3%)例.脱发:治疗组19(51.4%)例,对照组21(75.0%)例;肝功能异常:治疗组2(5.4%)例,对照组7(25.0%)例.ECG异常:治疗组 0例,对照组3(10.7%)例.口腔溃疡:治疗组 4(10.8%)例,对照组9(32.1%)例.结论 TA方案治疗急性髓性白血病较DA方案缓解率更高,毒副反应较DA方案更轻,但骨髓抑制时间长,感染发生率及出血性机会较DA方案高.     

吉非替尼治疗表皮生长因子受体突变型非小细胞肺癌患者的效果及影响因素

目的分析吉非替尼治疗表皮生长因子受体突变型非小细胞肺癌患者的效果及影响因素。方法选取湘南学院附属医院2020年1月-2021年6月收治的78例表皮生长因子受体突变型非小细胞肺癌患者作为观察对象。78例患者的临床治疗药物均为吉非替尼,均治疗六个疗程。观察78例患者治疗后的治疗效果以及不良反应发生情况,比较其治疗前后的生活质量(Karnofsky功能状态评分)变化,并对可能会影响其治疗效果的相关因素进行单因素分析和多因素Logistic分析。结果78例患者中,治疗效果为CR的例数为15例、PR的例数为10例、SD的例数为35例、PD的例数为18例,治疗效果良好率为32.05%(25/78)。78例患者治疗后,共计15例患者发生消化道反应,占比19.23%,8例患者发生皮疹,占比10.26%,2例患者发生肝功能异常,占比2.56%,及时经过对症处理后不良反应均明显改善,未对患者治疗及生活质量带来明显影响。和治疗前相比,78例患者治疗后的Karnofsky功能状态评分明显提升,差异有统计学意义(P<0.05)。相较于治疗效果良好的患者,治疗效果差的患者其在性别、肿瘤分期、病理类型以及肿瘤直径方面比较存在明显差异(P均<0.05),多因素Logistic分析结果显示男性、肿瘤分期为Ⅳ期、病理类型为鳞癌以及肿瘤直径>3cm是影响患者治疗效果的独立危险因素(P均<0.05)。结论对于表皮生长因子受体突变型非小细胞肺癌患者,吉非替尼治疗效果较为良好,不易对患者带来严重不良反应,但是在治疗期间,男性、肿瘤分期为Ⅳ期、病理类型为鳞癌以及肿瘤直径>3cm是影响其治疗效果的独立危险因素,临床需要提高重视。